Arix Bioscience Stock

Arix Bioscience ROE

Delisted·Feb 9, 2024

The Return on Equity (ROE) of Arix Bioscience (ARIX.L) as of Aug 23, 2026 is -12.21 %. In the previous year, Return on Equity (ROE) was -23.92 % — a change of -48.96% (higher).

ROE

-12.21 %

YoY

-48.96%

Last updated:

In 2026, Arix Bioscience's return on equity (ROE) was -12.21 %, a -48.96% increase from the -23.92 % ROE in the previous year.

The Arix Bioscience ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
-9.29 GBP
Jan 1, 2016
-19.09 GBP
Jan 1, 2017
-5.10 GBP
Jan 1, 2018
13.65 GBP
Jan 1, 2019
-34.48 GBP
Jan 1, 2020
38.48 GBP
Jan 1, 2021
-23.92 GBP
Jan 1, 2022
-12.21 GBP
The Arix Bioscience ROE history
YEARROEYoY
-12.21 %-48.96%
-23.92 %-162.15%
38.48 %-211.60%
-34.48 %-352.64%
13.65 %-367.50%
-5.10 %-73.28%
-19.09 %+105.48%
-9.29 %
Access this data via the Eulerpool API

Arix Bioscience Stock analysis

What does Arix Bioscience do? Arix Bioscience PLC is a leading investment and management provider in the biotech industry. The company is focused on identifying, investing in, and growing emerging companies to develop groundbreaking therapies for patients worldwide. The firm was founded in 2016 in London, United Kingdom, and has since focused on collaborating with emerging biotech companies. Arix is now one of the fastest-growing biotech companies in the region, with locations in London, New York, and Zug, Switzerland. Arix Bioscience's business model is based on investing in young biotechnology companies and supporting their growth. The goal is to develop new drugs and therapies by driving innovation in the biotech industry, ultimately benefiting patients worldwide, including those with rare or incurable diseases. To achieve these goals, Arix Bioscience operates in three divisions: Investment, Management, and Discovery. The Investment division actively invests in young biotech companies that aim to develop and commercialize groundbreaking therapies and new diagnostic methods. The company not only provides financial resources but also has extensive experience in the biotech industry and a variety of contacts to offer advisory support when needed. The Management division focuses on effectively managing investments in young biotech companies to fully unleash their growth potential. Arix Bioscience assists these companies, for example, in finding suitable candidates for leadership positions, planning clinical trials, or exploring new markets. The Discovery division specifically targets the discovery and development of new therapies and medications. The company works directly with biotech startups to create a comprehensive value chain that spans from the discovery and exploration of drug molecules to clinical validation. To achieve these goals, Arix Bioscience collaborates closely with leading biotech startups and research institutions worldwide. The company has extensive relationships and networks in the biotech industry, allowing it to optimize the support it provides to its portfolios. Among the products provided by Arix Bioscience is a portfolio of drugs and therapies developed by the biotech companies in which Arix has invested. These portfolios include successful products such as the CD19 CAR-T therapy developed by Autolus Therapeutics, which is used in cancer treatment. Another example is MiroBio, a company in which Arix Bioscience has invested to develop a new medication for autoimmune diseases. Here too, Arix Bioscience has utilized its investment and management expertise to successfully support the company's growth. Overall, Arix Bioscience is a company with a clear focus on innovation and growth in the biotech industry. The company actively invests in emerging biotech startups and provides targeted management and comprehensive support to lead them to great successes. With its extensive experience, Arix Bioscience has become an important player in the development of new therapies and medications. Arix Bioscience is one of the most popular companies on Eulerpool.

ROE Details

Decoding Arix Bioscience's Return on Equity (ROE)

Arix Bioscience's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Arix Bioscience's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Arix Bioscience's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Arix Bioscience’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Arix Bioscience stock

Return on Equity (ROE) of Arix Bioscience is -12.21 % in 2026.

Return on Equity (ROE) of Arix Bioscience changed from -23.92 % to -12.21 %, representing a -48.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Arix Bioscience since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Arix Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Arix Bioscience

All Key Metrics — Arix Bioscience